Developer docs
API playgroundTry for free, no card

Search company profiles

Integrum

Full company profile

uuid0002m4w

Namestring
Integrum
Legal namestring
Integrum AB
Websiteurl
integrum.se
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Integrum AB is a Swedish, publicly traded medical technology company (Nasdaq First North Growth Market, ticker INTEG B) that develops and commercializes bone-anchored prosthetic systems based on osseointegration, in which a titanium implant integrates directly with the patient's residual bone to attach a prosthetic limb without a socket. The company's flagship product, the OPRA Implant System — comprising a Fixture (titanium implant), an Abutment (skin-penetrating connector) and an Abutment Screw — incorporates the proprietary BioHelix surface technology and BondedMatrix biological barrier. OPRA received CE marking in 2000 and FDA Premarket Approval in 2020, making Integrum the only company with an FDA-approved bone-anchored prosthesis system for amputees in the United States.

The business monetizes primarily through hardware sales of the OPRA implant kits and ancillary surgical instruments to certified Centers of Excellence and hospitals, complemented by surgeon training and professional services. Distribution is direct to ~50+ medical centers globally — including Johns Hopkins, Walter Reed, Shirley Ryan AbilityLab, Cedars-Sinai, UCLA, and Mayo Clinic — with anchor contracts such as a 2018 SEK 60M (five-year) frame agreement with the US Department of Defense. The next-generation e-OPRA platform, which combines osseointegration with targeted muscle reinnervation (TMR) and neural signal decoding for intuitive prosthetic control, is currently in clinical trials in the US, and a new subsidiary called Afyri was spun out in 2026 to commercialize AI-based bionic interface technology.

Following 2025 leadership changes (new CEO Martin Hillsten) and an October 2025 restructuring that eliminated six Swedish roles, Integrum is positioning itself as a streamlined, commercially focused organization scaling US sales via a new patient portal with integrated CRM. Geographic expansion is underway into Ukraine (national osseointegration pilot announced 2026) and beyond the existing footprint in Western Europe, North America, Australia, the Middle East, and South America. The company reports persistent operating losses (Q4 EBIT approximately -SEK 20M, ~-SEK 5M adjusted) and continues to finance commercial scaling through equity issuance and bridge loans.

Short descriptiontext

Integrum AB is a Swedish public medical-technology company that develops FDA-approved, bone-anchored prosthetic systems (the OPRA Implant System) for amputees, selling directly to a global network of certified Centers of Excellence and serving both military and civilian patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMölndal, Sweden
HQ citystring
Mölndal
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
osseointegration implants, bone-anchored prosthetics, orthopedic implant systems, prosthetic limb attachment, medical device manufacturing
Industry2 codes
PRIMARYHLAHAMAD
Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHSADAIAN
Prosthetics/Orthotics Rehab & Amputee Rehabilitation
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthopedic Implant Systems
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1OPRA Implant System Sales
TypeHardware Sales
Description

Sale of bone-anchored prosthetic implant systems to medical centers and hospitals. Revenue generated from surgical implants performed at certified Centers of Excellence worldwide.

integrum.se
2Surgical Instruments and Components
TypeHardware Sales
Description

Sale of specialized components and surgical instruments tailored to different indication levels for both upper and lower limb applications.

investors.integrum.se
3Professional Services and Training
TypeProfessional Services
Description

Training and support services for surgeons performing OPRA implant surgeries at medical centers.

integrum.se
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Medical device pricing negotiated with healthcare institutions
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; medical device sales are typically negotiated with hospitals and medical centers on a case-by-case or contract basis.

integrum.se
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Afyri
Description

Subsidiary focused on bionics, e-OPRA technology, and AI-based platform for the interface between human and prosthesis.

investors.integrum.se
+3 more records
Core offering1 text field

Integrum develops, manufactures, and sells the OPRA Implant System, a bone-anchored prosthesis system that uses osseointegration technology to attach prosthetic limbs directly to the patient's skeleton, eliminating the need for conventional socket prostheses. The system includes the FDA-approved (PMA, 2020) and CE-marked OPRA Implant System for transfemoral amputees, the investigational e-OPRA Implant System combining osseointegration with neural interfaces for above-elbow amputees, proprietary BioHelix surface technology, and the BondedMatrix biological barrier. The company distributes through a global network of certified Centers of Excellence and provides surgical training and rehabilitation support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 92% success rate at 2-year follow-up
+3 more records
Product overview1 text field

Integrum offers a portfolio of bone-anchored prosthetic systems centered on the OPRA™ Implant System, a FDA-approved (2020) and CE-marked medical device enabling direct skeletal attachment of prosthetics without socket-based solutions. The portfolio includes the core OPRA™ system (with BioHelix™ surface and BondedMatrix™ technology), the investigational e-OPRA™ system combining osseointegration with neural interfaces for enhanced prosthetic control, and the Axor connection device for lower limbs. The company operates through subsidiary Afyri for AI/bionics development and offers a patient-facing digital portal integrated with CRM systems for sales process management.

Product and service6 records
1OPRA Implant System
CategoryBone-Anchored Prosthetic Implant System
Description

FDA-approved and CE-marked bone-anchored prosthesis system enabling direct skeletal attachment of prosthetic limbs. Consists of a titanium Fixture implanted into the bone, a skin-penetrating Abutment, and an Abutment Screw, using BioHelix surface technology and BondedMatrix barrier. Sold to certified medical centers performing OPRA surgeries for transfemoral amputees.

2e-OPRA Implant System
CategoryNeural-Enabled Prosthetic Implant System
Description

Next-generation bone-anchored prosthetic system combining osseointegration with targeted muscle reinnervation (TMR) and neural interfaces for intuitive prosthetic control. Currently in clinical trials for above-elbow amputees.

3BioHelix Surface Technology
CategoryImplant Surface Technology
Description

Proprietary titanium implant surface technology that promotes faster, stronger bone attachment and increases strength of the bone-to-implant interface. Licensed as part of the OPRA Implant System offering.

4BondedMatrix Biological Barrier
CategoryImplant Interface Technology
Description

Biologically integrated barrier forming at the skin-bone interface at the penetration site following healing. Unique to Integrum's surgical technique.

5Axor Connection Device
CategoryProsthetic Connection Component
Description

Connection device for the OPRA Implant System tailored to lower limb applications.

6Patient Portal with CRM Integration
CategoryDigital Patient Engagement Platform
Description

Digital patient-facing platform supporting patient identification, communication with patients and families, tracking patient inquiries, and guiding patients through the healthcare process from initial contact to implantation.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Leading US rehabilitation hospital conducting first-ever home trial combining osseointegration and targeted muscle reinnervation (TMR) for above-elbow amputees using Integrum's e-OPRA implant system. The five-year clinical study is supported by NIH grant of USD 8.7 million to Shirley Ryan AbilityLab. Eight participants enrolled to test bionic arm control through bone-anchored implants, nerve rewiring, and internal sensors.

2Ukrainian Government Healthcare System
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

Ukrainian government published draft decision for nationwide osseointegration pilot project. Two-year pilot covering full clinical pathway including surgery reimbursement, rehabilitation, implant system financing, and long-term follow-up. Muscle and nerve interface technologies referenced in infrastructure planning.

investors.integrum.se
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Frame agreement worth SEK 60 million over five years signed with US Department of Defense. Integrum participates in research programs with the Regenerative Medicine Department at Naval Medical Research Center, Walter Reed National Military Medical Center for bone-anchored prostheses for military amputees.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Department of Biomaterials at University of Gothenburg for development of BioHelix surface technology. Also involved in research with UCSF where Professor Rickard Brånemark serves as visiting professor.

5Afyri
Strategic tierCoreTypeStrategic or Co-development Partner
Description

New subsidiary being established to unlock potential within e-OPRA and create an AI-based platform for the interface between human and prosthesis. This subsidiary will accelerate development within bionics.

integrum.se
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in prosthetics and orthotics with a competing bone-anchored/percutaneous osseointegration prosthetic solution (Intuitive EO). Direct head-to-head competitor in the same product category serving amputee patients with similar osseointegration-based approach.

TypeDirect peer
Description

Major prosthetics manufacturer offering socket-based and bionic limb solutions for lower and upper extremity amputees. Comparable as it serves the same amputee patient population with prosthetic devices, though focused on socket-based versus bone-anchored approaches.

TypeDirect peer
Description

Now part of Stryker, Stanmore developed the STIMULITE and ITAP bone-anchored prosthetic systems. Directly competes with Integrum in osseointegration-based limb restoration for amputee patients.

4Hanger Clinic
TypeBroad incumbent
Description

Largest US provider of prosthetic and orthotic patient care services, including fitting and clinical support for osseointegration candidates. Comparable as it serves the same amputee patient flow, though focused on clinical services rather than the implant device itself.

TypeBroad incumbent
Description

Broad orthopedic and rehabilitation device manufacturer with prosthetic and bracing products serving amputee populations. Comparable as an adjacent medtech player in orthopedic and rehabilitation devices, though with a much broader portfolio beyond osseointegration.

TypeBroad incumbent
Description

Global orthopedic implant leader spanning joint reconstruction, trauma, and surgical specialties. Comparable as a major medtech incumbent with the scale and orthopedic salesforce to enter bone-anchored prosthetics if the category scales.

TypeBroad incumbent
Description

Major orthopedic medical device company with a dedicated orthopedic implants and surgical equipment portfolio, including the Stanmore bone-anchored prosthetic line. Comparable as a large incumbent with overlapping orthopedic focus and existing osseointegration product line.

TypeBroad incumbent
Description

Global medical device company active in orthopedic reconstruction, sports medicine, and wound management. Comparable as a broad orthopedic incumbent with the channel and capital to compete in adjacent implant categories.

TypeBroad incumbent
Description

Spinal and orthopedic implant company with biologics and limb reconstruction products. Comparable as a focused orthopedic implant peer serving surgeons and hospitals, though with a different core portfolio (spine, bone growth stimulation).

10Exactech
TypeEmerging player
Description

Smaller orthopedic implant company focused on joint replacement and extremity solutions. Comparable as a similarly-sized orthopedic implant player in adjacent reconstructive categories, with potential overlap if Integrum expands beyond amputee-specific indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Integrum

Orthopedic Implant Systemsintegrum.se

Integrum AB is a Swedish public medical-technology company that develops FDA-approved, bone-anchored prosthetic systems (the OPRA Implant System) for amputees, selling directly to a global network of certified Centers of Excellence and serving both military and civilian patients.

What Integrum does

Integrum AB is a Swedish, publicly traded medical technology company (Nasdaq First North Growth Market, ticker INTEG B) that develops and commercializes bone-anchored prosthetic systems based on osseointegration, in which a titanium implant integrates directly with the patient's residual bone to attach a prosthetic limb without a socket. The company's flagship product, the OPRA Implant System — comprising a Fixture (titanium implant), an Abutment (skin-penetrating connector) and an Abutment Screw — incorporates the proprietary BioHelix surface technology and BondedMatrix biological barrier. OPRA received CE marking in 2000 and FDA Premarket Approval in 2020, making Integrum the only company with an FDA-approved bone-anchored prosthesis system for amputees in the United States.

The business monetizes primarily through hardware sales of the OPRA implant kits and ancillary surgical instruments to certified Centers of Excellence and hospitals, complemented by surgeon training and professional services. Distribution is direct to ~50+ medical centers globally — including Johns Hopkins, Walter Reed, Shirley Ryan AbilityLab, Cedars-Sinai, UCLA, and Mayo Clinic — with anchor contracts such as a 2018 SEK 60M (five-year) frame agreement with the US Department of Defense. The next-generation e-OPRA platform, which combines osseointegration with targeted muscle reinnervation (TMR) and neural signal decoding for intuitive prosthetic control, is currently in clinical trials in the US, and a new subsidiary called Afyri was spun out in 2026 to commercialize AI-based bionic interface technology.

Following 2025 leadership changes (new CEO Martin Hillsten) and an October 2025 restructuring that eliminated six Swedish roles, Integrum is positioning itself as a streamlined, commercially focused organization scaling US sales via a new patient portal with integrated CRM. Geographic expansion is underway into Ukraine (national osseointegration pilot announced 2026) and beyond the existing footprint in Western Europe, North America, Australia, the Middle East, and South America. The company reports persistent operating losses (Q4 EBIT approximately -SEK 20M, ~-SEK 5M adjusted) and continues to finance commercial scaling through equity issuance and bridge loans.

Integrum firmographics

Firmographics
Name
Integrum
Legal name
Integrum AB
Website
https://integrum.se
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
51–100 employees
Short description
Integrum AB is a Swedish public medical-technology company that develops FDA-approved, bone-anchored prosthetic systems (the OPRA Implant System) for amputees, selling directly to a global network of certified Centers of Excellence and serving both military and civilian patients.
Ownership category
akta.pro rank

Integrum industry classification

Industry
Product category
Orthopedic Implant Systems
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAMAD
Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHSADAIAN
Prosthetics/Orthotics Rehab & Amputee Rehabilitation
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise

Keywords

  • Osseointegration implants
  • Bone-anchored prosthetics
  • Orthopedic implant systems
  • Prosthetic limb attachment
  • Medical device manufacturing

Where Integrum is headquartered

Location

Headquarters

HQ city
Mölndal
HQ country
Sweden
HQ region
Europe

Offices3 records

Markets served

Integrum business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. OPRA Implant System Sales: Sale of bone-anchored prosthetic implant systems to medical centers and hospitals. Revenue generated from surgical implants performed at certified Centers of Excellence worldwide.
  2. Surgical Instruments and Components: Sale of specialized components and surgical instruments tailored to different indication levels for both upper and lower limb applications.
  3. Professional Services and Training: Training and support services for surgeons performing OPRA implant surgeries at medical centers.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMedical device pricing negotiated with healthcare institutions

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Integrum product offering

Product offering

Core offering

Integrum develops, manufactures, and sells the OPRA Implant System, a bone-anchored prosthesis system that uses osseointegration technology to attach prosthetic limbs directly to the patient's skeleton, eliminating the need for conventional socket prostheses. The system includes the FDA-approved (PMA, 2020) and CE-marked OPRA Implant System for transfemoral amputees, the investigational e-OPRA Implant System combining osseointegration with neural interfaces for above-elbow amputees, proprietary BioHelix surface technology, and the BondedMatrix biological barrier. The company distributes through a global network of certified Centers of Excellence and provides surgical training and rehabilitation support.

Product overview

Integrum offers a portfolio of bone-anchored prosthetic systems centered on the OPRA™ Implant System, a FDA-approved (2020) and CE-marked medical device enabling direct skeletal attachment of prosthetics without socket-based solutions. The portfolio includes the core OPRA™ system (with BioHelix™ surface and BondedMatrix™ technology), the investigational e-OPRA™ system combining osseointegration with neural interfaces for enhanced prosthetic control, and the Axor connection device for lower limbs. The company operates through subsidiary Afyri for AI/bionics development and offers a patient-facing digital portal integrated with CRM systems for sales process management.

Differentiator

Problem solved

Functional benefit

Brands

  • Afyri: Subsidiary focused on bionics, e-OPRA technology, and AI-based platform for the interface between human and prosthesis.
  • OPRA Implant System
  • BioHelix
  • e-OPRA Implant System

Products and services

  • OPRA Implant System FDA-approved and CE-marked bone-anchored prosthesis system enabling direct skeletal attachment of prosthetic limbs. Consists of a titanium Fixture implanted into the bone, a skin-penetrating Abutment, and an Abutment Screw, using BioHelix surface technology and BondedMatrix barrier. Sold to certified medical centers performing OPRA surgeries for transfemoral amputees.
  • e-OPRA Implant System Next-generation bone-anchored prosthetic system combining osseointegration with targeted muscle reinnervation (TMR) and neural interfaces for intuitive prosthetic control. Currently in clinical trials for above-elbow amputees.
  • BioHelix Surface Technology Proprietary titanium implant surface technology that promotes faster, stronger bone attachment and increases strength of the bone-to-implant interface. Licensed as part of the OPRA Implant System offering.
  • BondedMatrix Biological Barrier Biologically integrated barrier forming at the skin-bone interface at the penetration site following healing. Unique to Integrum's surgical technique.
  • Axor Connection Device Connection device for the OPRA Implant System tailored to lower limb applications.
  • Patient Portal with CRM Integration Digital patient-facing platform supporting patient identification, communication with patients and families, tracking patient inquiries, and guiding patients through the healthcare process from initial contact to implantation.

Quantifiable outcome

  • 92% success rate at 2-year follow-up
  • +3 more outcomes

Companies that use Integrum

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles4 records

Integrum technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Integrum partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Shirley Ryan AbilityLabcoreStrategic or Co-development Partner · 10 June 2026Leading US rehabilitation hospital conducting first-ever home trial combining osseointegration and targeted muscle reinnervation (TMR) for above-elbow amputees using Integrum's e-OPRA implant system. The five-year clinical study is supported by NIH grant of USD 8.7 million to Shirley Ryan AbilityLab. Eight participants enrolled to test bionic arm control through bone-anchored implants, nerve rewiring, and internal sensors.
  • Ukrainian Government Healthcare SystemcoreStrategic or Co-development Partner · 26 May 2026Ukrainian government published draft decision for nationwide osseointegration pilot project. Two-year pilot covering full clinical pathway including surgery reimbursement, rehabilitation, implant system financing, and long-term follow-up. Muscle and nerve interface technologies referenced in infrastructure planning.
  • US Department of DefensecoreStrategic or Co-development Partner · 1 January 2018Frame agreement worth SEK 60 million over five years signed with US Department of Defense. Integrum participates in research programs with the Regenerative Medicine Department at Naval Medical Research Center, Walter Reed National Military Medical Center for bone-anchored prostheses for military amputees.
  • University of GothenburgcoreStrategic or Co-development PartnerCollaboration with Department of Biomaterials at University of Gothenburg for development of BioHelix surface technology. Also involved in research with UCSF where Professor Rickard Brånemark serves as visiting professor.
  • AfyricoreStrategic or Co-development PartnerNew subsidiary being established to unlock potential within e-OPRA and create an AI-based platform for the interface between human and prosthesis. This subsidiary will accelerate development within bionics.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Integrum competitors and assessment

Company assessment

Direct peers

  • Ottobock: Global leader in prosthetics and orthotics with a competing bone-anchored/percutaneous osseointegration prosthetic solution (Intuitive EO). Direct head-to-head competitor in the same product category serving amputee patients with similar osseointegration-based approach.
  • Össur: Major prosthetics manufacturer offering socket-based and bionic limb solutions for lower and upper extremity amputees. Comparable as it serves the same amputee patient population with prosthetic devices, though focused on socket-based versus bone-anchored approaches.
  • Stanmore Implants (Stryker): Now part of Stryker, Stanmore developed the STIMULITE and ITAP bone-anchored prosthetic systems. Directly competes with Integrum in osseointegration-based limb restoration for amputee patients.

Broad incumbents

  • Hanger Clinic: Largest US provider of prosthetic and orthotic patient care services, including fitting and clinical support for osseointegration candidates. Comparable as it serves the same amputee patient flow, though focused on clinical services rather than the implant device itself.
  • DJO (Enovis): Broad orthopedic and rehabilitation device manufacturer with prosthetic and bracing products serving amputee populations. Comparable as an adjacent medtech player in orthopedic and rehabilitation devices, though with a much broader portfolio beyond osseointegration.
  • Zimmer Biomet: Global orthopedic implant leader spanning joint reconstruction, trauma, and surgical specialties. Comparable as a major medtech incumbent with the scale and orthopedic salesforce to enter bone-anchored prosthetics if the category scales.
  • Stryker: Major orthopedic medical device company with a dedicated orthopedic implants and surgical equipment portfolio, including the Stanmore bone-anchored prosthetic line. Comparable as a large incumbent with overlapping orthopedic focus and existing osseointegration product line.
  • Smith+Nephew: Global medical device company active in orthopedic reconstruction, sports medicine, and wound management. Comparable as a broad orthopedic incumbent with the channel and capital to compete in adjacent implant categories.
  • Orthofix Medical: Spinal and orthopedic implant company with biologics and limb reconstruction products. Comparable as a focused orthopedic implant peer serving surgeons and hospitals, though with a different core portfolio (spine, bone growth stimulation).

Emerging players

  • Exactech: Smaller orthopedic implant company focused on joint replacement and extremity solutions. Comparable as a similarly-sized orthopedic implant player in adjacent reconstructive categories, with potential overlap if Integrum expands beyond amputee-specific indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Integrum social profiles

Digital presence

Integrum compliance and trust

Trust signal

Compliance2 records

Integrum financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Integrum leadership team

Management profile

Number of profiles

Profiles10 records

Integrum subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Integrum funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Integrum M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integrum

What does Integrum do?

Integrum develops, manufactures, and sells the OPRA Implant System, a bone-anchored prosthesis system that uses osseointegration technology to attach prosthetic limbs directly to the patient's skeleton, eliminating the need for conventional socket prostheses. The system includes the FDA-approved (PMA, 2020) and CE-marked OPRA Implant System for transfemoral amputees, the investigational e-OPRA Implant System combining osseointegration with neural interfaces for above-elbow amputees, proprietary BioHelix surface technology, and the BondedMatrix biological barrier. The company distributes through a global network of certified Centers of Excellence and provides surgical training and rehabilitation support.

Is Integrum a public or private company?

Integrum is a public company. It is classified as public and is currently operating.

When was Integrum founded?

Integrum was founded in 1999. It employs 51 to 100 people.

Where is Integrum based?

Integrum is headquartered in Mölndal, Sweden, in the Europe region.

How does Integrum make money?

Three revenue lines are on record. OPRA Implant System Sales are the primary driver. The others are surgical Instruments and Components and professional Services and Training.

Who are Integrum's main competitors?

Direct peers on record are Ottobock, Össur and Stanmore Implants (Stryker). Broad incumbents are Hanger Clinic, DJO (Enovis), Zimmer Biomet, Stryker, Smith+Nephew and Orthofix Medical. Exactech is listed as an emerging player.

Does Integrum have an API?

No public API is recorded for Integrum.

What industry is Integrum in?

Integrum's product category is Orthopedic Implant Systems. Its primary akta.pro industry code is HLAHAMAD, Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets), with a secondary code of HSADAIAN, Prosthetics/Orthotics Rehab & Amputee Rehabilitation. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingIntegrum Legacy Sponsor of the GCCO 2026 – hosts OPRA surgical training and leads symposium on the Ukrainian experienceIntegrum AB is the Legacy Sponsor of the fifth GCCO 2026 in Charlotte, hosting an OPRA surgical training course and a symposium on the Ukrainian experience. The symposium, led by Dr. Rickard Brånemark, covers 100 cases in Ukraine, where OPRA has been used in over 100 treatments since 2023.The future of tradingIntegrum says OPRA implant study in Ukrainian war veterans shows 97.9% survival at 1 year after S2Integrum reported a clinical study of its OPRA implant system in Ukrainian war veterans with combat-related amputations, showing 97.9% survival at one year. The study found no mechanical failures, though some post-surgery infections occurred. The results support Integrum's push in Ukraine, where bone-anchored prostheses are entering a state-funded pilot program.The future of tradingNew clinical study shows high implant survival with the OPRA Implant System in war-injured veterans in UkraineIntegrum AB announced a clinical study of its OPRA Implant System in Ukrainian war veterans, published in International Orthopaedics. The study of 49 veterans showed a 97.9% implant survival rate one year after the second surgical stage, with 93.2% survival at 18.7 months. The results support continued use of the system in Ukraine.AffarsvarldenIntegrum gör riktad nyemissionIntegrum issued a rights issue of about 2.7 million B-shares at 8.60 kronor per share, with investors including Cicero Fonder, Nowo Fund Management, and Nordic Compound Invest. The capital will accelerate commercialization of OPRA Implant System in the US, pursue opportunities in Ukraine, and fund strategic initiatives, with a 9.1% dilution.MarketScreenerIntegrum raises nearly $2.1m through a directed share issueIntegrum raised nearly $2.1m through a directed share issue of about 2.7 million class B shares at 8.60 kronor each. The capital will accelerate commercialization of the OPRA Implant System in the US, capture opportunities in Ukraine, and finance strategic initiatives. The issue results in about 9.1% dilution.Dagens industriIntegrum vände till plusIntegrum reported a Q1 2026/2027 operating result of 1.3 million SEK (minus 12.4 million) for the first quarter of the broken fiscal year. Manager Henrik Carlman said it was the worst start of his career, but he remains optimistic about the future.Dagens industriFirst North-bolaget har fått tullåterbetalningThe medical technology company Integrum, listed on First North and developing systems for bone-anchored prostheses, has received an initial customs duty refund of approximately 2.6 million kronor from the US customs authority. The refund was received on June 16, 2026. The article does not provide further context on why the refund was issued or its implications for the company's operations.news.cision.comIntegrum accelerates Ukraine expansion following landmark decision to expand osseointegration treatment in national healthcareIntegrum appointed Victoria Boiko to coordinate its Ukraine commercial activities, as Ukraine's Ministry of Health prepares a national pilot project to integrate osseointegration into public healthcare. Since May 2023, Ukrainian surgeons have performed 100 procedures with Integrum's OPRA Implant System, and procedures are planned in Kyiv, Lviv, and Cherkasy.news.cision.comIntegrum optimizes organization to further accelerate commercialization of OPRA Implant SystemSwedish medtech company Integrum AB announced organizational changes to accelerate commercialization of its FDA-approved OPRA Implant System, a bone-anchored prosthetic device for amputees. Jeff Zanni, President US, is departing the company while Dr. Rickard Brånemark transitions to a consulting Chief Medical and Scientific Officer role, and Per Nilsson will join as Chief Supply Chain Officer on March 16, 2026. The restructuring focuses on scaling US sales through patient identification and digitalization initiatives while streamlining global production and supply chain operations.news.cision.comIntegrum’s rights issue oversubscribedIntegrum AB announced that its rights issue was oversubscribed, raising approximately SEK 42.7 million, with strong support from shareholders. The company will issue 5,333,582 new shares, increasing its total share capital and diluting existing shareholders by 20%.